392 related articles for article (PubMed ID: 16485039)
1. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.
Savage DB; Choi CS; Samuel VT; Liu ZX; Zhang D; Wang A; Zhang XM; Cline GW; Yu XX; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Clin Invest; 2006 Mar; 116(3):817-24. PubMed ID: 16485039
[TBL] [Abstract][Full Text] [Related]
2. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
3. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
[TBL] [Abstract][Full Text] [Related]
4. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
5. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.
Abu-Elheiga L; Wu H; Gu Z; Bressler R; Wakil SJ
J Biol Chem; 2012 Apr; 287(15):12578-88. PubMed ID: 22362781
[TBL] [Abstract][Full Text] [Related]
8. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase.
Glien M; Haschke G; Schroeter K; Pfenninger A; Zoller G; Keil S; Müller M; Herling AW; Schmoll D
Horm Metab Res; 2011 Aug; 43(9):601-6. PubMed ID: 21823054
[TBL] [Abstract][Full Text] [Related]
10. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal.
Abu-Elheiga L; Matzuk MM; Kordari P; Oh W; Shaikenov T; Gu Z; Wakil SJ
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12011-6. PubMed ID: 16103361
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Harriman G; Greenwood J; Bhat S; Huang X; Wang R; Paul D; Tong L; Saha AK; Westlin WF; Kapeller R; Harwood HJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1796-805. PubMed ID: 26976583
[TBL] [Abstract][Full Text] [Related]
12. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
13. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription.
Zhao LF; Iwasaki Y; Zhe W; Nishiyama M; Taguchi T; Tsugita M; Kambayashi M; Hashimoto K; Terada Y
Endocr J; 2010; 57(4):317-24. PubMed ID: 20139635
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-CoA carboxylase 2 inhibition reduces skeletal muscle bioactive lipid content and attenuates progression of type 2 diabetes in Zucker diabetic fatty rats.
Takagi H; Ikehara T; Hashimoto K; Tanimoto K; Shimazaki A; Kashiwagi Y; Sakamoto S; Yukioka H
Eur J Pharmacol; 2021 Nov; 910():174451. PubMed ID: 34454928
[TBL] [Abstract][Full Text] [Related]
15. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
[TBL] [Abstract][Full Text] [Related]
16. Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance.
Popov VB; Jornayvaz FR; Akgul EO; Kanda S; Jurczak MJ; Zhang D; Abudukadier A; Majumdar SK; Guigni B; Petersen KF; Manchem VP; Bhanot S; Shulman GI; Samuel VT
FASEB J; 2016 Mar; 30(3):1207-17. PubMed ID: 26644352
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets.
Abu-Elheiga L; Oh W; Kordari P; Wakil SJ
Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10207-12. PubMed ID: 12920182
[TBL] [Abstract][Full Text] [Related]
18. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
19. Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis.
Zhang H; Li Y; Hu J; Shen WJ; Singh M; Hou X; Bittner A; Bittner S; Cortez Y; Tabassum J; Kraemer FB; Azhar S
PLoS One; 2015; 10(9):e0138203. PubMed ID: 26394137
[TBL] [Abstract][Full Text] [Related]
20. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.
Abu-Elheiga L; Matzuk MM; Abo-Hashema KA; Wakil SJ
Science; 2001 Mar; 291(5513):2613-6. PubMed ID: 11283375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
